Compare STRIDES PHARMA SCIENCE with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs NATCO PHARMA - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE NATCO PHARMA STRIDES PHARMA SCIENCE/
NATCO PHARMA
 
P/E (TTM) x 14.5 15.6 93.4% View Chart
P/BV x 0.9 3.1 28.1% View Chart
Dividend Yield % 0.6 1.5 38.8%  

Financials

 STRIDES PHARMA SCIENCE   NATCO PHARMA
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
NATCO PHARMA
Mar-18
STRIDES PHARMA SCIENCE/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,1471,080 106.2%   
Low Rs642671 95.6%   
Sales per share (Unadj.) Rs317.2592.1 53.6%  
Earnings per share (Unadj.) Rs7.8188.4 4.2%  
Cash flow per share (Unadj.) Rs25.1206.3 12.1%  
Dividends per share (Unadj.) Rs2.008.25 24.2%  
Dividend yield (eoy) %0.20.9 23.7%  
Book value per share (Unadj.) Rs274.3833.6 32.9%  
Shares outstanding (eoy) m89.5036.90 242.5%   
Bonus/Rights/Conversions ESOPIS-  
Price / Sales ratio x2.81.5 190.6%   
Avg P/E ratio x114.04.6 2,453.3%  
P/CF ratio (eoy) x35.74.2 841.3%  
Price / Book Value ratio x3.31.1 310.5%  
Dividend payout %25.54.4 582.2%   
Avg Mkt Cap Rs m80,05832,311 247.8%   
No. of employees `0002.54.8 51.9%   
Total wages/salary Rs m4,3413,256 133.3%   
Avg. sales/employee Rs Th11,325.84,522.5 250.4%   
Avg. wages/employee Rs Th1,731.4674.0 256.9%   
Avg. net profit/employee Rs Th280.11,439.0 19.5%   
INCOME DATA
Net Sales Rs m28,39421,848 130.0%  
Other income Rs m941404 232.8%   
Total revenues Rs m29,33422,252 131.8%   
Gross profit Rs m3,9659,284 42.7%  
Depreciation Rs m1,540662 232.7%   
Interest Rs m1,962154 1,274.3%   
Profit before tax Rs m1,4038,872 15.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m971,920 5.1%   
Profit after tax Rs m7026,952 10.1%  
Gross profit margin %14.042.5 32.9%  
Effective tax rate %6.921.6 32.0%   
Net profit margin %2.531.8 7.8%  
BALANCE SHEET DATA
Current assets Rs m24,83621,307 116.6%   
Current liabilities Rs m18,9935,920 320.8%   
Net working cap to sales %20.670.4 29.2%  
Current ratio x1.33.6 36.3%  
Inventory Days Days7173 96.9%  
Debtors Days Days113107 106.5%  
Net fixed assets Rs m34,28914,986 228.8%   
Share capital Rs m895369 242.5%   
"Free" reserves Rs m23,65130,353 77.9%   
Net worth Rs m24,54630,760 79.8%   
Long term debt Rs m15,5130-   
Total assets Rs m65,43737,151 176.1%  
Interest coverage x1.758.6 2.9%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.40.6 73.8%   
Return on assets %4.119.1 21.3%  
Return on equity %2.922.6 12.7%  
Return on capital %6.929.3 23.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,69710,322 152.1%   
Fx outflow Rs m7352,978 24.7%   
Net fx Rs m14,9627,343 203.7%   
CASH FLOW
From Operations Rs m1,8714,636 40.4%  
From Investments Rs m5,826-11,155 -52.2%  
From Financial Activity Rs m-10,1576,509 -156.0%  
Net Cashflow Rs m-2,615-18 14,527.2%  

Share Holding

Indian Promoters % 27.7 52.0 53.2%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 37.8 7.8 482.1%  
FIIs % 8.6 16.6 51.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 26.0 99.6%  
Shareholders   56,241 25,395 221.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   PIRAMAL ENTERPRISES  NOVARTIS  PANACEA BIOTECH  DR. REDDYS LAB  GSK PHARMA  

Compare STRIDES PHARMA SCIENCE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Oct 18, 2019 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 5-YR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS